Odevixibat: First Approval

Emma D. Deeks

Published online: 9 September 2021
© Springer Nature 2021, corrected publication 2021

Abstract
Odevixibat (Bylvay™) is a small molecule inhibitor of the ileal bile acid transporter being developed by Albireo Pharma, Inc. for the treatment of various cholestatic diseases, including progressive familial intrahepatic cholestasis (PFIC). In July 2021, odevixibat received its first approval in the EU for the treatment of PFIC in patients aged ≥ 6 months, followed shortly by its approval in the USA for the treatment of pruritus in patients aged ≥ 3 months with PFIC. Odevixibat is also in clinical development for the treatment of other cholestatic diseases, including Alagille syndrome and biliary atresia, in various countries. This article summarizes the milestones in the development of odevixibat leading to this first approval for PFIC.

1 Introduction
Cholestatic liver diseases are typified by the accumulation of biliary components resulting from impaired bile formation and/or bile flow, with liver injury, inflammation and fibrosis being driven largely by bile acid (BA) retention [1, 2]. Symptoms can include pruritus, fatigue and jaundice, with progression to end stage liver disease in many cases requiring liver transplant [3]. Asymptomatic cases can also occur and are often identified by elevated levels of certain liver enzymes upon routine laboratory testing or tests for another condition [3].

Odevixibat (Bylvay™) is a small molecule inhibitor of the ileal BA transporter (IBAT) [4, 5]. Odevixibat is being developed by Albireo Pharma, Inc. (Albireo) for the treatment of cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia and Alagille syndrome. In July 2021, odevixibat was approved in the EU for the treatment of PFIC in patients aged ≥ 6 months [5, 6] and in the USA for the treatment of pruritus in patients aged ≥ 3 months with PFIC [4, 7]. Odevixibat is available as 4 strengths in 2 different sized capsules; smaller capsules (400 and 1200 µg) are intended to be swallowed, while the larger capsules (200 and 600 µg strength) are intended to be opened and the contents (oral pellets) sprinkled on soft food [4, 5]. The recommended dosage is 40 µg/kg once daily, administered orally in the morning, with (EU; USA) [4, 5] or without (EU) [5] food. In the

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Emma D. Deeks
dru@adis.com

1 Springer Nature, Mairangi Bay, Private Bag 65901, Auckland 0754, New Zealand
EU and US, if an adequate clinical response has not been achieved after 3 months of continuous therapy with odevixibat, the dose may be increased to 120 µg/kg/day [4, 5]; in the US this can be achieved by increasing the dose in increments of 40 µg/kg [4]. The maximum daily dose of odevixibat is 7.2 mg per day in the EU [5] and the daily dose must not exceed 6 mg in the US [4].

Odevixibat continues to be assessed for PFIC in an ongoing open-label, phase III extension study for long term safety and efficacy, and is also in phase III development for other cholestatic diseases, including Alagille syndrome and biliary atresia. Odevixibat has orphan designations for the treatment of Alagille syndrome, biliary atresia and primary biliary cholangitis in both the USA and EU [8–10].

1.1 Company Agreements and Patent Information

In February 2021, Albireo entered into a limited co-promotion agreement (for 2 years, with option of extending) with Travere Therapeutics in the USA [11] and entered a marketing agreement with Medison Pharma Ltd for commercialization of odevixibat in Israel [12]. In May 2021, Albireo also entered into license and distribution agreements for the commercialization of odevixibat with Genpharm Services (in Saudi Arabia and other Gulf countries) and Gen Ilac (in Turkey) [13].

In 2006, Albireo was issued patents covering the composition-of-matter for odevixibat in the USA and > 50 other countries, and in May 2017 was issued a method-of-treatment patent for odevixibat in PFIC and other specified liver diseases in the USA, corresponding method-of-use patents in Europe and Japan, and a method-of-treatment patent in NASH in the USA [14]. As of December 2020, Albireo has patent protection for odevixibat composition-of-matter expiring in September 2022, and protection in the USA for the method of using certain IBAT inhibitor(s) to treat certain liver diseases, expiring in November 2031, not including a patent term extension. Albireo also has a European patent for the method of using certain IBAT inhibitor(s) in combination with a BA binder to treat certain liver diseases (expires November 2031), with the same patent pending in the USA. An Albireo patent for crystal modifications of odevixibat is now issued in the USA (expiring in June 2039) and is currently pending in Europe. Similarly, patents for formulations of odevixibat are pending in the USA and Europe and, if granted, will expire in June 2039 [10].

2 Scientific Summary

2.1 Pharmacodynamics

Odevixibat displays selective, reversible inhibition of the IBAT [5]. The drug reduces the level of BAs in the plasma/serum by reducing the reuptake of BAs in the distal ileum...
and increasing colon clearance of BAs [5, 15]. There is no
correlation between the degree by which serum BA (sBA)
levels are reduced and the systemic pharmacokinetics of
odevixibat, given the drug acts locally in the intestine with
minimal systemic exposure [5].

In a mouse model of sclerosing cholangitis, odevixi-
bat ameliorated cholestatic liver and bile duct injury and
appeared to have anti-fibrotic as well as anti-inflammatory
effects [16].

2.2 Pharmacokinetics

After oral administration, odevixibat absorption is mini-
mal [4, 5]. In paediatric patients with PFIC aged 0.5–17
years treated once daily with odevixibat 40 or 120 µg/kg,
plasma concentrations of odevixibat were generally
below the limit of quantification [4]. Simulated in a pae-
diatric PFIC population, odevixibat 40 or 120 µg/kg/day
had maximum plasma concentrations of 0.21 and 0.62 ng/mL
and area under the plasma concentration-time-curve values
of 2.26 and 5.99 ng · h/mL [5]. Taking odevixibat with food,
or after sprinkling odevixibat pellets on soft food, has no
clinically relevant impact on systemic exposure to the drug
[4]. There is minimal [5] to no [4] accumulation of odevi-
xbat after once-daily administration. Odevixibat is > 99%
plasma protein bound [4, 5]. Dosages of 40 or 120 µg/kg/day
have mean bodyweight-adjusted apparent volumes of dis-
tribution of 40.3 and 43.7 L/kg in paediatric patients [5].
Metabolism of odevixibat is minimal in humans [5], and
occurs via mono-hydroxylation in vitro [4]. In healthy
adults, elimination of odevixibat after a single oral dose
occurred mainly via the faeces (82.9%), with only 0.002% of
the dose eliminated via the urine [17]. In paediatric patients
who received odevixibat 40 or 120 µg/kg/day, the mean
bodyweight-normalized apparent total clearance values
were 26.4 and 23.0 L/kg/h; the mean half-life of the drug
is ≈ 2.5 h [5].

Absorption of fat-soluble vitamins (FSVs) may be
reduced by odevixibat; monitoring of FSVs is therefore
advised [4, 5]. Similarly, odevixibat may impact the
absorption of lipophilic oral contraceptives and other fat-
soluble medications [5]. Odevixibat may be bound by BA-

binding resins in the gut; thus, staggered administration
is recommended [4]. Odevixibat is a P-glycoprotein substrate
[4, 5]; its exposure may therefore increase if coadminis-
tered with the strong P-glycoprotein inhibitor itraconazole,
although this interaction is not expected to be clinically
relevant [18, 19]. Although odevixibat is an inhibitor of
CYP3A4/5, it does not alter exposure to the CYP3A4 sub-
strate midazolam [4, 5, 19] or its 1-hydroxy metabolite [4,
5] to any clinically relevant extent.

2.3 Therapeutic Trials

2.3.1 Progressive Familial Intrahepatic Cholestasis

Odevixibat was effective in reducing pruritus and sBAs in
children with PFIC in a randomized, double-blind, phase
III trial (NCT03566238; PEDFIC 1) [5, 20]. Patients aged
0.5–18 years with PFIC (type 1 or 2), elevated sBAs and a
history of significant pruritus were randomized to odevixi-
bat 40 µg/kg (n = 23), odevixibat 120 µg/kg (n = 19) or pla-
celo (n = 20) once daily [20]. Over the 24-week treatment
period, the mean proportion of positive pruritus assessments
(defined as a scratching score of ≤ 1 or ≥ 1-point improve-
ment from baseline on a 5-point scale of an observer-
reported instrument) [primary endpoint in USA] was

| Features and properties of odevixibat |
|--------------------------------------|
| Alternative names                   | Bylvay; A4250 |
| Class                                | Acetamides, butyric acids, hepatoprotectants, small molecules, sulfones, thiazepines |
| Mechanism of action                 | Sodium-bile acid cotransporter inhibitors |
| Route of administration             | Oral |
| Pharmacodynamics                    | Selectively and reversibly inhibits the ileal BA transporter; reduces BA levels in serum/plasma by reducing BA reuptake in the distal ileum and increasing colon clearance of BAs |
| Pharmacokinetics                    | Minimal absorption and metabolism; eliminated mainly via the faeces; half-life ≈ 2.5 h |
| Most frequent adverse events        | Diarrhoea, increased hepatic enzymes (including alanine transferase and aspartate transferase), increased blood bilirubin, increased international normalized ratio |
| ATC codes                           | WHO ATC code: A05A-X05 (odevixibat) |
| EphMRA ATC code                     | A5A (bile therapy and cholagogues) |
| Chemical name                       | (S)-2-((R)-2-(2-(3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[f][1,2,5]thiadiazepin-8-yl)oxy)acetamido)-2-(4-hydroxyphenyl)acetamido)butanoic acid |

BA bile acid
58.3% with odevixibat 40 µg/kg/day, 47.7% with odevixibat 120 µg/kg/day and 28.7% with placebo, with the difference between each odevixibat group and placebo being significant (based on 95% CIs) [5]. In addition, significantly (one-sided \( p < 0.02 \)) more patients achieved an sBA response (defined as a ≥ 70% reduction from baseline or a level ≤ 70 µmol/L at week 24) [primary endpoint in Europe/rest of world] with odevixibat 40 µg/kg/day (43.5%; 10/23 patients) or 120 µg/kg/day (21.1%; 4/19 patients) than with placebo (0%; 0/20 patients). Each odevixibat dosage group had favourable mean changes from baseline in growth parameters, including height and weight Z scores, versus placebo, although the between-group differences were not significant [5]. Odevixibat appeared to improve both patient and family health-related quality of life (QoL), as assessed by caregivers of patients aged ≥ 2 years using the Pediatric QoL Inventory questionnaire, with mean improvements from baseline in both total score and family impact total score numerically favouring odevixibat (40 and 120 µg/kg/day pooled) over placebo [21].

Longer-term clinical benefit of odevixibat has been demonstrated in an ongoing, open-label, phase III, extension study (NCT03659916; PEDFIC 2) [22]. Patients in this trial either had PFIC type 1 or 2 and had been treated with odevixibat (40 or 120 µg/kg/day) \( (n = 34) \) or placebo \( (n = 19) \) in the PEDFIC 1 trial or were new patients with any type of PFIC \( (n = 16) \). The previously treated patients were defined as the P1O cohort, whereas the latter two patient groups were combined into a single ‘treatment-naïve’ (TN) cohort. All patients received odevixibat 120 µg/kg/day in the extension study. In an interim analysis (data cutoff July 2020), mean sBA levels in the P1O cohort significantly \( (p < 0.0001) \) declined from 251.8 µmol/L at the PEDFIC 1 baseline to 85.1 µmol/L after 24 weeks of treatment in the extension (i.e. total of 48 weeks’ therapy). In the P1O cohort, there were also significant improvements in mean monthly pruritus scores (from 3.0 to 1.4, \( p < 0.0001 \)), height Z scores (from −1.6 to −0.5, \( p = 0.02 \)) and weight Z scores (from −0.9 to 0.2, \( p = 0.03 \)) [22, 23]. Data for these outcomes in the TN cohort over the course of the extension (i.e. over 24 weeks’ treatment) showed a similar trend [22, 23].

The efficacy of odevixibat has been further assessed in a pooled analysis of the PEDFIC 1 and 2 trials [24–26]. This analysis included 77 patients who received odevixibat in one or both of the studies; 42 were treated with the drug in PEDFIC 1 (34 of these entered PEDFIC 2), 19 had received placebo in PEDFIC 1 (all entered PEDFIC 2) and 16 were patients newly enrolled into PEDFIC 2. In this analysis, improvements in sBA and pruritus were observed with odevixibat regardless of whether patients had type 1 \( (n = 20) \) or type 2 \( (n = 51) \) PFIC [24]; the improvements occurred within the first 4 weeks of treatment and were sustained up to week 48 [25, 26]. In addition to improvements in sBA and pruritus, there were also continued clinically meaningful benefits seen in terms of growth, and sleep parameters over 48 weeks of treatment [26].

### 2.3.2 Other Cholestatic Disease Studies

Odevixibat demonstrated promise as a treatment for paediatric patients with various cholestatic liver diseases and pruritus in an open-label, multicentre, phase II study (NCT02630875) [27]. Eligible patients were aged 1–18 years with pruritus caused by a chronic cholestatic disease (e.g. PFIC, Alagille syndrome, biliary atresia or primary sclerosing cholangitis). Patients received a single dose of odevixibat (10–200 µg/kg, depending on the cohort) prior to a 2-week safety observation period, then received that same dose daily for 4 weeks; 20 patients participated, with 4 entering the study again after completing their first dose level. At the end of the 4-week treatment period, overall (i.e. all cohorts combined), the mean change from baseline in sBA

---

**Key clinical trials of odevixibat (all sponsored by Albireo Pharma, Inc.)**

| Drug(s) | Indication | Phase | Status | Location(s) | Identifier |
|---------|------------|-------|--------|-------------|------------|
| Odevixibat, placebo | PFIC (type 1 or 2) | III | Completed | Multinational | NCT03566238; PEDFIC 1; EudraCT2017-002338-21 |
| Odevixibat | PFIC (any type) | III | Recruiting | Multinational | NCT03659916; PEDFIC 2; EudraCT2017-002325-38 |
| Odevixibat, placebo | Alagille syndrome | III | Recruiting | Multinational | NCT04674761; ASSERT; EudraCT2020-004011-28 |
| Odevixibat, placebo | Biliary atresia | III | Recruiting | Multinational | NCT04336722; BOLD; EudraCT2019-003807-37 |
| Odevixibat | Cholestasis | II | Completed | Europe | NCT02630875; EudraCT2015-001157-32 |

*PFIC* progressive familial intrahepatic cholestasis

\( \Delta \) Adis
level (primary endpoint) was −123.1 µmol/L (235 µmol/L at baseline). Mean changes from baseline in pruritus scores were −2.2 on the visual analogue-itch scale (baseline 6.2; 0–10 scale), −2.0 on the Partial Patient-Oriented Scoring Atopic Dermatitis itch scale (baseline 6.0; 0–10 scale) and −0.8 on the Whittington itch scale (baseline 2.6; 0–4 scale); lower scores indicate improvements [27].

2.4 Adverse Events

Odevixibat was generally well tolerated in paediatric patients with cholestatic liver diseases in clinical studies [20, 23, 27, 28], with the focus here being the phase III PEDFIC 1 and 2 trials.

In the 24-week PEDFIC 1 study, 33.3% of all odevixibat (40 or 120 µg/kg/day) recipients and 15.0% of placebo recipients had treatment-related adverse events (AEs) [28]. The most common of these to occur with odevixibat included diarrhoea, alanine aminotransferase (ALT) increased, blood bilirubin increased (incidence of each was 8.7% [2/23 patients] with 40 µg/kg/day and 10.5% [2/19] with 120 µg/kg/day vs 5.0% [1/20] with placebo) and aspartate aminotransferase increased (8.7% [2/23] with 40 µg/kg/day and 5.3% [1/19] with 120 µg/kg/day vs 5.0% [1/20] with placebo). One discontinuation occurred (in the odevixibat 120 µg/kg/day arm) because of an AE (diarrhoea) [28].

The tolerability profile of odevixibat in the PEDFIC 2 extension study was consistent with these findings. Interim tolerability data from PEDFIC 2 were grouped into two cohorts: patients who had received odevixibat (n = 34) or placebo (n = 19) in PEDFIC 1 (cohort 1) and patients who were newly enrolled into PEDFIC 2 (cohort 2; n = 16) [28]. The incidence of treatment-related AEs with odevixibat 120 µg/kg/day from 24 weeks was 26.3–31.3% across cohorts 1 and 2 and 29% (20/69 patients) overall. In cohort 1 the most common treatment-related AEs were blood bilirubin increased (8.8%; 3/34 patients) and hepatic enzyme increased (5.9%; 2/34 patients) in patients who had received odevixibat in PEDFIC 1, and blood bilirubin increased (10.5%; 2/19 patients) and ALT increased (5.3%; 1/19 patients) in patients who had received placebo in PEDFIC 1. Similarly, in cohort 2, blood bilirubin increased, ALT increased and international normalized ratio increased were the most frequent treatment-related AEs (12.5% incidence for each; 2/16 patients). One discontinuation occurred primarily because of an AE (worsening cholestasis) [28].

In PEDFIC 1 or 2, there were no liver decompensation events, new FSV deficiency events (refractory to clinically recommended vitamin supplementation), deaths or serious treatment-related AEs, and no clinically relevant changes in haematology, serum biochemistry or urinalysis test values [28].

2.5 Ongoing Clinical Trials

In addition to the previously discussed ongoing, open label, long-term phase III PEDFIC 2 trial (NCT03659916) evaluating the safety and efficacy of odevixibat, recruitment is underway in two phase III trials evaluating the efficacy and safety of odevixibat in children and adults with Alagille syndrome (NCT04674761; ASSERT) and children with biliary atresia who have undergone a Kasai hepatoportoenterostomy (NCT04336722; BOLD).

3 Current Status

Odevixibat received its first approval on 16 July 2021 for the treatment of PFIC in patients aged ≥ 6 months in the EU [5, 6] and on 20 July 2021 in the USA for the treatment of pruritus in patients aged ≥ 3 months with PFIC [4, 7].

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40265-021-01594-y.

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Karpen SJ, Kelly D, Mack C, et al. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020;14(5):677–89.
2. de Vries E, Beuers U. Management of cholestatic disease in 2017. Liver Int. 2017;37:123–9.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.
4. Albireo Pharma. Bylvay (odevixibat) capsules, for oral use: US prescribing information. 2021. https://albireopharma.com. Accessed 21 Jul 2021.
5. Albireo AB. Bylvay: EU prescribing information. 2021. https://albireopharma.com. Accessed 21 Jul 2021.
6. FirstWorld Pharma. Albireo receives European marketing authorization of Bylvay (odevixibat), the first drug treatment for progressive familial intrahepatic cholestasis (PFIC) [media release]. 19 Jul 2021. https://www.firstworldpharma.com.
7. Albireo Pharma. Multimedia update—Albireo announces FDA approval of Bylvay™ (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis (PFIC) [media release]. 20 Jul 2021. https://ir.albireopharma.com.
8. U.S. Food and Drug Administration. Orphan drug designations and approvals. 2021. https://www.accessdata.fda.gov/scripts/opa/ding/oop/detailedIndex.cfm?cfridkey=658118. Accessed 21 Jul 2021.
9. Albireo Pharma. Albireo granted orphan designation by European commission for lead product candidate A4250 for treatment of biliary atresia [media release]. 18 Dec 2018. http://www.albireopharma.com.
10. United States Securities and Exchange Commission. Form 10-K. Albireo Pharma, Inc. 2021. https://www.sec.gov/Archives/edgar/data/0001322505/000155837021001730/albo-20201231x10k.htm. Accessed 21 July 2021.
11. Albireo Pharma. Albireo reports Q4 and year-end 2020 financial results and business update [media release]. 25 Feb 2021. http://www.albireopharma.com.
12. Albireo Pharma. Albireo presents odevixibat commercialization road to $1 billion [media release]. 11 Feb 2021. www.albireopharma.com.
13. Albireo Pharma. Albireo reports Q1 financial results and business update [media release]. 6 May 2021. http://www.albireopharma.com.
14. Albireo Pharma. Albireo announces two new U.S. patents allowed for A4250 with term into 2031 [media release]. 16 May 2017. http://www.albireopharma.com.
15. Graffner H, Gillberg PG, Rikner L, et al. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment Pharmacol Ther. 2016;43(2):303–10.
16. Baghdasaryan A, Fuchs CD, Österreicher CH, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol. 2016;64(3):674–81.
17. Gillberg PG, Mattsson J, Torfgård K, et al. Clinical pharmacology of odevixibat, a potent, selective ileal bile acid transport inhibitor with minimal systemic exposure [abstract no. 167]. J Pediatric Gastroenterol Nutr. 2019;69(Suppl 2):113.
18. Stein P, Wright G, Kjemps L, et al. Drug-drug interaction study to evaluate the interaction of A4250 (odevixibat) with midazolam, a sensitive CYP3A4 substrate, and itraconazole, a P-gp inhibitor, in healthy adult subjects [abstract no. 638]. J Pediatric Gastroenterol Nutr. 2020;71(Suppl 1):S433–4.
19. Stein P, Wright G, Kjemps L, et al. Drug-drug interaction study to evaluate the interaction of A4250 (odevixibat) with midazolam, a sensitive CYP3A4 substrate, and itraconazole, a P-gp inhibitor, in healthy adult subjects [abstract no. H-ePwP-033]. J Pediatric Gastroenterol Nutr. 2021;72(Suppl 1):873–4.
20. Thompson R, Baumann U, Czubkowski P, et al. Efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis types 1 and 2: results from PEDFIC 1, a randomized, double-blind, placebo-controlled phase 3 trial [abstract no. LO4]. The Liver Meeting Digital Experience™. 2020. http://www.aasld.org/event/liver-meeting-digital-experience. Accessed 21 Jul 2021.
21. Thompson RJ, Kjemps L, Hardikar W, et al. Improved quality of life in children with progressive familial intrahepatic cholestasis following 24 weeks of treatment with odevixibat, an ileal bile acid transporter inhibitor: results from the phase 3 PEDFIC 1 study [abstract no. PMU62]. Value Health. 2021;24(Suppl 1):S155.
22. Thompson R, Artan R, D’Antiga L, et al. Long-term efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor in children with progressive familial intrahepatic cholestasis: interim results from PEDFIC 2, an open-label phase 3 trial [abstract no. LP19]. The Liver Meeting Digital Experience™. 2020. http://www.aasld.org/event/liver-meeting-digital-experience. Accessed 21 Jul 2021.
23. Thompson RJ, Verkade HJ, Gonzales E, et al. Long-term treatment benefits of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: improvements in total bilirubin, growth, and sleep as secondary and exploratory outcome measures from the phase 3 PEDFIC 1 and PEDFIC 2 studies [abstract no. H-O-030]. J Pediatric Gastroenterol Nutr. 2021;72(Suppl 1):819–20.
24. Thompson R, Horn P, Houwen RHJ, et al. Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies [abstract no. PO-1665 plus poster]. In: International Liver Congress. 2021.
25. Thompson R, D’Antiga L, Kamath BM, et al. Rapid and durable effect of odevixibat on clinical and biochemical parameters of cholestasis in children with progressive familial intrahepatic cholestasis [abstract no. OS-1554]. In: International Liver Congress. 2021.
26. Thompson R, D’Antiga L, Gonzales E, et al. Odevixibat therapy improves clinically meaningful endpoints in children with progressive familial intrahepatic cholestasis: data from the PEDFIC 1 and PEDFIC 2 trials [abstract no. PO-1833 plus poster]. In: International Liver Congress. 2021.
27. Baumann U, Sturm E, Lacaille F, et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin Res Hepatol Gastroenterol. 2021. https://doi.org/10.1016/j.clinre.2021.101751.
28. Grammatikopoulos T, Thompson C, Soufi N, et al. Long-term safety and tolerability of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: results from the phase 3 PEDFIC 1 and PEDFIC 2 studies [abstract no. H-O-011]. J Pediatric Gastroenterol Nutrition. 2021;72(Suppl 1):781–2.